The use and effectiveness of current stroke reperfusion therapies are limited by the complications of reperfusion injury, which include increased cerebrovascular permeability and hemorrhagic transformation. Sphingosine-1-phosphate (S1P) is emerging as a potent modulator of vascular integrity via its receptors (S1PR). By using genetic approaches and a S1PR2 antagonist (JTE013), here we show that S1PR2 plays a critical role in the induction of cerebrovascular permeability, development of intracerebral hemorrhage and neurovascular injury in experimental stroke. In addition, inhibition of S1PR2 results in decreased matrix metalloproteinase (MMP)-9 activity in vivo and lower gelatinase activity in cerebral microvessels. S1PR2 immunopositivity is detected only in the ischemic microvessels of wild-type mice and in the cerebrovascular endothelium of human brain autopsy samples. In vitro, S1PR2 potently regulates the responses of the brain endothelium to ischemic and inflammatory injury. Therapeutic targeting of this novel pathway could have important translational relevance to stroke patients.
INTRODUCTION
Stroke is a leading cause of death and long-term disability worldwide 1 . Despite many decades of intensive research, therapeutic options for patients presenting with ischemic stroke are very limited. Neuroprotective agents have been designed to block one or more steps of the neuronal ischemic cascade. However, none of these drugs unequivocally has shown an improvement in clinical outcomes 2, 3 . Currently, stroke therapies aim at establishing early reperfusion by thrombolytic (e.g. tissue Plasminogen Activator) and/or mechanical recanalization of obstructed blood vessel/s 4, 5 . However, restoration of blood flow exacerbates brain injury due to increased reactive oxygen species generation and further activation of matrix metalloproteases (MMP) with subsequent development of vasogenic edema (increased cerebrovascular permeability) and hemorrhagic transformation 5, 6 , two life-threatening complications which limit the use and effectiveness of stroke reperfusion strategies. Administration of vasoprotective agents at the time of reperfusion could potentially decrease the risk and the extent of these complications by improving the integrity of the injured cerebral blood vessels, which could ultimately result in improved stroke outcomes.
Ischemia-reperfusion (I/R) injury induces metabolic stress and inflammatory responses in the neurovascular unit. Although neurons are extremely sensitive to the lack of oxygen and nutrients, I/R injury also compromises the barrier properties of brain endothelial cells, which contributes to neurovascular pathophysiology by allowing the entrance of toxic plasma proteins and blood cells into the brain parenchyma 7 , increasing intracranial pressure and compromising the delivery of nutrients and oxygen. In the acute phase of stroke (minutes to hours) reactive oxygen species and pro-inflammatory cytokines released in the brain parenchyma, such as Tumor Necrosis Factor-α (TNF-α) or Interleukin-1β, are known to induce vascular permeability, adhesion molecule expression and the expression and activity of MMP, which exacerbate blood brain barrier disruption, worsening neurovascular injury 8, 9 . In the subacute phase, further disruption of blood vessel integrity occurs, leading to hemorrhagic transformation and exacerbation of neuronal injury 5 . In experimental models of stroke, activation of MMP and the subsequent degradation of endothelial basal lamina and tight junction proteins have been shown to play a critical role the disruption of cerebrovascular integrity 8, 10, 11 . Since MMP can be highly toxic molecules, they are tightly regulated at the transcriptional, translational and post-translational levels. Among MMP, MMP-2 is constitutively expressed in the brain and brain endothelial cells while basal MMP-9 levels are very low and rapidly induced by pro-inflammatory stimuli 12 . Although it is well established that MMP contribute to neurovascular injury in stroke, currently there are no therapies specifically targeting MMP, due to the complex regulation of MMP activity, as well as the lack of specificity of MMP inhibitors and their numerous side effects.
The bioactive sphingolipid, sphingosine-1-phosphate (S1P) is emerging as a potent modulator of vascular integrity. S1P is present at high levels (within the range of several hundred nanomolar) in plasma and lymph. It is generated from the metabolism of sphingomyelin through the actions of sphingomyelinase, ceramidase and sphingosine kinase (SPHK). Although platelets store high amounts of S1P, the main sources of plasma S1P are erythrocytes 13 and endothelial cells 14 , which exhibit high SPHK activity. S1P regulates many cellular functions via its interaction with the endothelial differentiation gene family of G protein-coupled receptors, renamed as S1PR1-5 15 . S1P binds to its receptors within the low nanomolar range (the K D of S1P for S1PRs ranges from 8-27nM). S1PR activate different intracellular signaling pathways and differentially regulate endothelial cell function. S1PR1 couples to G i and activates the phosphatidylinositol-3-kinase (PI3K) pathway 16 , which promotes vascular integrity [17] [18] [19] . In contrast, we found that S1PR2 antagonizes S1PR1-G i -PI3K signaling in the endothelium through activation of the G 12 -Rho pathway 20 and that S1PR2 is sufficient for endothelial activation in vitro 21 . The role of S1P in vascular development is well illustrated by S1pr1 null mice, which exhibit a defect in vascular maturation 18 . In adult mice, S1PR1 promotes vascular integrity 19 and regulates lymphocyte trafficking 22 . In fact, the recently FDA-approved Fingolimod, is a potent immunosuppressant via S1PR1. In contrast to S1PR1, S1PR2 is not required for embryonic vascular development and S1pr2 −/− mice are viable and develop normally 23 . In addition, using a model of acute inflammatory vascular injury, we recently reported that S1PR2 expression in the stromal/endothelial compartment, and not in hematopoietic cells, is critical for the induction of vascular permeability, endothelial activation and sustained systemic inflammation 21 , suggesting that S1PR2 could be a novel target for acute vascular protection in various clinical settings.
Herein, we aimed to assess the role of S1PR2 in the regulation of cerebrovascular integrity after ischemia-reperfusion (I/R) injury. Using a mouse model of focal transient cerebral ischemia, the middle cerebral artery occlusion model (MCAO), we report the critical role of S1PR2 in the disruption of cerebrovascular integrity after I/R injury. S1PR2 is induced in cerebral microvessels early after I/R injury. Our in vitro studies with mouse and human primary brain microvascular endothelial cells, mouse primary neurons and mouse primary mixed glial cells provide novel mechanistic insights into the regulation of cerebrovascular responses to I/R injury by S1PR2. Finally, we detect S1PR2 in the cerebrovascular endothelium in human autopsy specimens. Altogether our data point to S1PR2 as a novel therapeutic target for acute cerebrovascular protection in stroke.
RESULTS

Critical role of S1PR2 in neuronal injury and edema in experimental stroke
In order to study the role of S1PR2 signaling in the regulation of neurovascular responses to I/R injury, we used a mouse model of transient focal cerebral ischemia, the transient middle cerebral artery occlusion (tMCAO) mouse model of stroke. S1pr2 +/+ and S1pr2 −/− littermates were subjected to transient focal ischemia for 90 minutes. 24 hours after reperfusion, infarct and edema ratios were quantified in wild type and S1pr2 −/− mice as previously described 24 . As shown in Figure 1A -C, S1pr2 −/− mice exhibited a dramatic decrease in both infarct ratio (wild type 0.324± 0.053 vs S1pr2 null 0.084±0.017, 74% reduction, p<0.05, one-way ANOVA followed by Newman-Keuls test) and total cerebral edema ratio (wild type 0.121± 0.011 vs S1pr2 −/− 0.047±0.008, 61.2% reduction, p<0.05, one-way ANOVA followed by Newman-Keuls test), which is the sum of cytotoxic and vasogenic edema. In addition, S1pr2 −/− mice exhibited improved neurological scores compared to wild type (Figure1D). We also found that the infarct size was significantly reduced and the neurological scores were significantly improved in S1pr2 null mice compared to wild type, 5 days after tMCAO (Supplementary Figure 1A-D) .
In order to evaluate the therapeutic targeting of S1PR2 in stroke reperfusion therapies, we acutely inhibited S1PR2 activation by administration of the S1PR2 antagonist, JTE013 by gavage. In agreement with our data in S1pr2 null mice, administration of the S1PR2 antagonist (30mg/kg) 10 minutes after reperfusion (1.7 hours after the onset of ischemia) in wild type mice resulted in a dramatic decrease in both infarct and edema ratios (79.6% and 81.03% inhibition, respectively, Figure 1A -C), as well as in a significant improvement of the neurological scores ( Figure 1D ). Consistent with our recent studies using sepsis models 21 , the minimum effective dose of JTE013 was 30 mg/kg (Supplementary Figure 2) . Mortality was <5% in all cohorts of mice 24 hours after reperfusion.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays showed a significant decrease in TUNEL-positive cells both in S1pr2 −/− and JTE013-treated S1pr2 +/+ mice (508.7±74 and 639±98 positive cells per mm 2 , respectively) compared to vehicle-treated wild-type mice (949±73 positive cells per mm 2 )( Figure 1E , F), indicating that inhibition of S1PR2 decreases DNA fragmentation that results from apoptosis after I/R injury. No TUNEL positive cells were detected in the contralateral hemisphere (not shown).
No significant differences were observed in the physiological parameters (Arterial O 2 saturation, heart rate, pulse distention and respiratory rate) between wild type and S1pr2 −/− mice, before, during or after MCAO (Table 1 ). In addition, cerebral blood flow (CBF) in the territory of the middle cerebral artery, monitored during the surgeries by Laser Doppler, was similarly reduced in all three groups of mice during occlusion (13% ± 1.2 of basal level) and similarly restored after reperfusion in wild type, S1pr −/− and JTE013-treated wild type mice (94.6% ± 1.1 of basal) ( Figure 2 ).
In order to determine the therapeutic time window of JTE013 in experimental stroke, we assessed the edema and infarct ratios after delayed administration of the S1PR2 antagonist. We found that JTE013 administration 4.5 hours after ischemia resulted in the same significant reduction of brain infarct and edema ratios compared to 1.7 hours or S1pr2 −/− groups (no statistically significant differences were found between the 4.5 hour, 1.7 hour and S1pr2 −/− groups, Supplementary Figure 3 ), indicating that JTE013 was efficacious in reducing brain infarct and edema when administered within 4.5 hours after stroke. Administration of JTE013 at 7.5 h after the onset of ischemia had reduced efficacy and did not lead to statistically significant lower infarct sizes compared to the vehicle-treated group, indicating that JTE013 is protective when given within 4.5 hours of stroke onset.
Critical role of S1PR2 in the disruption of neurovascular integrity after I/R injury in vivo During cerebral ischemia, blood brain barrier disruption starts early after the onset of ischemia and increased cerebrovascular permeability can be detected as early as 3 hours after reperfusion 25, 26 . In order to investigate the role of S1PR2 in vasogenic edema (increased cerebrovascular permeability), we conducted Evans Blue Dye (EBD) extravasation assays. As shown in Figure 3A and B, S1pr2 −/− mice exhibited a dramatic decrease in EBD extravasation, 3 hours after reperfusion, compared to their wild type litter mates (ratio of EBD content in ipsilateral hemisphere/contralateral hemisphere was 1.6±0.31 in S1pr2 −/− mice vs 4.54±0.83 in wild type). In addition, acute inhibition of S1PR2 signaling in wild type mice, by JTE013 administration, potently blocked the induction of cerebrovascular permeability after I/R injury (ratio of EBD content 1.28±0.08, Figure 3A , B).
Increasing clinical evidence indicates that areas of the brain with compromised blood brain barrier at the early stages of ischemic stroke often undergo hemorrhagic transformation following reperfusion [27] [28] [29] [30] . In order to study the role of S1PR2 in the development of intracerebral hemorrhage after I/R injury, we used a model of spontaneous hemorrhagic transformation. Mice were subjected to 3 hours of ischemia to induce severe neurovascular injury. Upon this prolonged time of ischemia, a significant loss of cerebrovascular integrity was observed 24 hours after reperfusion in wild type mice ( Figure 3C, D) , as assessed by the presence of extravascular blood in the ischemic hemisphere (448± 96.4 mg Hemoglobin) compared to the contralateral hemisphere (182±23.9 mg hemoglobin/hemisphere). The ipsilateral/contralateral ratio was 2.68± 0.74 in wild type mice ( Figure 3D ). In sharp contrast, intracerebral hemorrhage was almost absent in S1pr2 −/− mice (ipsilateral/ contralateral ratio 1.01± 0.17, ~80% inhibition). In addition, acute inhibition of S1PR2 by oral administration of JTE013, 10 minutes after reperfusion, dramatically inhibited the development of intracerebral hemorrhage (ipsilateral/contralateral ratio 1.04± 0.05). The mortality rate at 24 hours after a 3-hour occlusion was 39% in vehicle-treated wild type mice, 20% in S1pr2 −/− and 18.2 % in wild type mice treated with JTE013.
These data indicate the critical role of S1PR2 in the disruption of cerebrovascular integrity after I/R injury in the brain, suggesting that S1PR2 could be targeted in stroke patients at the time of reperfusion to reduce cerebrovascular permeability and hemorrhagic transformation.
Critical role of S1PR2 in MMP-9 activation after I/R injury in vivo
In order to elucidate the mechanisms of regulation of cerebrovascular integrity by S1PR2, we determined the activation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B), also known as type IV collagenases, since they play a critical role in increased cerebrovascular permeability after I/R injury 31, 32 . In wild type animals, MMP-9 activity was significantly increased in brain lysates 3 hours after I/R injury, compared to sham animals ( Figure 4A and B). Interestingly, S1pr2 −/− mice exhibited significantly decreased MMP-9 activity compared to wild type (56±10% inhibition). Similarly, in JTE013-treated wild type mice, MMP-9 activity was significantly lower compared to vehicle-treated wild type mice (57±6.9% inhibition). In contrast, we did not detect a significant increase in MMP-2 activity in total brain lysates after I/R compared to sham animals or differences in MMP-2 activity between wild type and S1pr2 −/− mice or JTE013-treated mice 3 hours after reperfusion. These data indicate that S1PR2 plays a critical role in the induction of MMP-9 activity in brain lysates after I/R injury. In situ zymography assays revealed a dramatic increase in gelatinase activity both in cerebral microvessels and in brain parenchyma in the damaged area in vehicle-treated wild type mice, 3 hours after reperfusion ( Figure 4C ) (no signal was detected in sham animals or in the contralateral hemisphere). Interestingly, S1pr2 −/− and JTE013-treated S1pr2 +/+ mice exhibited much lower gelatinase activity in cerebral microvessels, consistent with the decreased cerebrovascular integrity observed in the EBD cerebrovascular permeability assay. Representative pictures of the damaged area at the level of bregma +1mm (rostrally) are shown, as indicated in Figure 1G . Altogether these data indicate that S1PR2 plays a critical role in MMP-9 activation and the induction of gelatinase activity in cerebral microvessels after I/R injury in experimental stroke.
Detection of S1PR2 in cerebral microvessels after I/R injury
We next aimed to assess the expression of S1PR2 in the mouse brain after I/R injury. In total brain lysates, we found that S1PR2 mRNA basal levels were low (0.37±0.03 mRNA copies/10 6 18s mRNA) but were significantly increased in the ischemic hemisphere after I/R injury (2.6±0.37 and 3.1±0.35 fold at 6 and 24 hours, respectively, Figure 5A ). Consistent with this mRNA data, we detected S1PR2 protein 6 hours after I/R injury by immunofluorescence analysis only in the ischemic hemisphere of wild type mice ( Figure  5B ). Representative pictures of the damaged area (corpus callosum and striatum) at the level of bregma +1mm (as indicated in Figure 1G ) are shown ( Figure 5B and Supplementary Figure 4A , respectively). S1PR2 positivity colocalized with CD31 staining ( Figure 5B and Supplementary Figure 4A ). No S1PR2 immuno-positivity was detected in the contralateral hemisphere 6 hours after I/R injury ( Figure 5C and Supplementary Figure 4B ), in the ispilateral hemisphere of S1pr2 −/− mice ( Figure 5D and Supplementary Figure 4C ) or in sham animals. These data indicate that S1PR2 upregulation in cerebral microvessels is an early event after I/R injury.
Critical role of S1PR2 in brain endothelial cell responses to I/R injury in vitro
Given our in vivo findings in mice, we next aimed to study the role of S1PR2 in the regulation of the responses of brain endothelial cells to I/R injury in vitro. We used the mouse brain microvascular endothelial cell line, bEnd3 33 and human primary brain microvascular endothelial cells (hBMVEC). In order to mimic in vitro the metabolic and inflammatory stress of I/R injury, we conducted oxygen and glucose deprivation (OGD) experiments (in vitro I/R) as well as TNF-α activation studies. In vitro I/R injury or TNF-α activation resulted in upregulation of S1PR2 message (2-and 3.5-fold respectively) both in bEnd3 and hBMVEC ( Figure 6A and B). In order to study the role of S1PR2 in brain endothelial cell permeability, bEnd3 cells were exposed to hypoxia/aglycemia (OGD) for 6 hours. Then, we measured changes in endothelial resistance upon in vitro reperfusion, using the electrical cell-substrate impedance sensing system (ECIS) (Applied BioPhysics, NY) 34 . As shown in Figure 6C , in vehicle-treated cells, endothelial resistance starts to decrease 10 hours after in vitro reperfusion and remains lower compared to control (normoxia, Figure  6D ). However, inhibition of S1PR2 signaling by JTE013 abrogated the decrease in monolayer resistance observed after in vitro I/R injury ( Figure 6C ), indicating the critical role of S1PR2 in the induction of brain endothelial cell monolayer permeability after in vitro I/R injury. JTE013 treatment did not affect endothelial resistance under normoxic conditions ( Figure 6D ). These experiments were conducted in the presence of serum, which contains S1P. In addition, since endothelial cells exhibit high levels of SPHK activity 19 and are one of the main sources of plasma S1P 14 it is possible that endothelial cell-derived S1P activates S1PR in an autocrine way, as we have previously described 20 .
Given that our in vitro model demonstrated similar S1PR2-mediated vascular responses to I/R injury as to those observed in vivo, we next investigated the role of S1PR2 in MMP activation in brain endothelial cells. Activation of human brain endothelial cells with TNF-α (5ng/mL) for 24 hours resulted in increased MMP-9 activity in the conditioned media compared to vehicle-treated cells (5.8±1.2 fold induction, Figure 6E ). In addition, TNF-α treatment induced the cleavage of pro-MMP2 (72 kDa) into the 67 and 64 kDa cleaved active forms (2.3±0.3 fold vs control). Blockade of S1PR2 signaling by JTE013 (1μM) 20 significantly decreased MMP-9 activity in the conditioned media, while it did not significantly change the levels of the cleaved active MMP-2 forms ( Figure 6E ). Consistent with the MMP activity data in endothelial conditioned media, we found that MMP-9 mRNA levels in brain endothelial cells were low under basal conditions and upregulated by TNF-α (Supplementary Figure 5A) , while MMP-2 mRNA levels were constitutively high and not affected by TNF-α (Supplementary Figure 5B) . Also, JTE013 partially inhibited the induction of MMP-9 mRNA by TNF-α, while it did not affect MMP-2 mRNA levels. These data are consistent with the critical role of S1PR2 in endothelial activation 21 . Using a gainof-function approach, we found that upregulation of S1PR2 levels by adenoviral transduction in hBMVEC resulted in increased levels of MMP-9 mRNA and MMP-9 activity (Supplementary Figure 5C -D) compared to control adenovirus-transduced cells (β-Galactosidase, β-Gal). These data indicate that S1PR2 upregulation in brain endothelial cells is sufficient for the induction of MMP-9 mRNA and MMP-9 activity in endothelial cell conditioned media. Altogether our in vitro data indicate that S1PR2 plays a critical role in the induction of brain endothelial cell permeability after I/R injury and activation of MMP-9.
Lack of a critical role of S1PR2 in neuronal and glial responses to I/R injury in vitro
In order to assess the role of S1PR2 in the regulation of neuronal and glial responses to ischemic and inflammatory injury, we isolated and cultured mouse cortical primary neurons from embryos (E 17.5) and mixed glial cells from pups (post natal day 2). In vitro I/R injury (4 hours of OGD followed by in vitro reperfusion) did not significantly change the levels of S1PR2 mRNA in mouse cortical primary neurons ( Figure 7A ). In addition, blockade of S1PR2 signaling by JTE013 did not inhibit neuronal cell death induced by in vitro I/R injury, assessed by LDH activity in neuronal supernatants ( Figure 7B ), while α-phenyl-tertbutyl nitrone α-(PBN), a neuroprotective spin trap agent that reacts with and trap free radicals 35 , did inhibit. Similarly, neuronal cell death induced by H 2 O 2 was not affected by JTE013 but it was inhibited by α-PBN ( Figure 7C ). In mouse primary mixed glial cells, activation with TNF-α did not significantly increase the levels of S1PR2 mRNA ( Figure 7D ) while it significantly induced the expression of other pro-inflammatory molecules, such as interleukin 1β ( Figure 7E ). In addition, we found that JTE013 did not affect the inflammatory responses of mouse primary mixed glial cells. As shown in Figure 7F , the induction of MMP-9 activity by TNF-α in glial cell supernatants was not inhibited by the S1PR2 antagonist, JTE013. These data indicate that S1PR2 is not critical for the regulation of neuronal and glial responses to ischemic and inflammatory injury in vitro. Altogether our in vitro data with brain endothelial cells, neurons and glial cells indicate that S1PR2 plays a critical role in the responses of brain endothelial cells to I/R injury.
Expression of S1PR2 in human brain samples
Given our in vivo and in vitro findings, in order to assess their potential pathophysiological relevance in humans, we performed immunohistochemical (IHC) analysis of S1PR2 in human brain autopsy samples. The specificity of the S1PR2 antibody was determined as we have previously described 36 : S1PR2 immunohistochemistry showed membranous and cytoplasmic staining only in S1PR2-transfected 293T cells and not in S1PR1-transfected or pcDNA3.1-transfected cells (Supplementary Figure 6) . IHC analysis of human brain samples revealed S1PR2 positivity in the cerebrovascular endothelium ( Figure 8 , representative pictures). We found heterogeneous S1PR2 expression in the endothelium of pial vessels and microvessels throughout the brain in the 5 brain samples analyzed. The limited clinical data available for these patients (summarized in Supplementary Table 1) revealed various hypoxic/ischemic states including stroke, respiratory failure or sickle cell vaso-occlusive crisis. These data indicate that S1PR2 can be detected in the human cerebrovascular endothelium.
DISCUSSION
In this study, we have identified the critical role of S1PR2 in the disruption of neurovascular integrity after I/R injury. We found that genetic deletion or pharmacological inhibition of S1PR2 promoted cerebrovascular integrity in a mouse model of transient cerebral ischemia (tMCAO), resulting in decreased neuronal death and improved neurological scores. Inhibition of S1PR2 potently blocked the development of cerebral edema and spontaneous hemorrhagic transformation in experimental stroke. We also found that S1PR2 protein is induced in cerebral microvessels in mice in the early stages after I/R injury. In addition, our in vivo and in vitro data provide mechanistic insights into the regulation of cerebrovascular permeability by S1PR2. In vivo, we found that genetic deletion or pharmacological inhibition of S1PR2 results in decreased MMP-9 activity in whole brain lysates and gelatinase (MMP-2/9) activity in cerebral microvessels, which is consistent with the decreased cerebrovascular permeability and hemorrhagic transformation observed in S1pr2 −/− mice or wild type mice treated with JTE013 compared to vehicle-treated wild type mice. Our in vitro studies indicate that S1PR2 plays a critical role in the responses of brain endothelial cells to I/R injury (i.e. permeability and MMP-9 activation) but not neurons or glial cells. In experimental stroke, MMP have been shown to play a critical role in blood brain barrier disruption and hemorrhagic transformation 10, 37, 38 . More specifically, MMP-9 levels and activity are increased early during cerebral ischemia 38 and mice lacking MMP-9 8 but not MMP-2 39 are protected in stroke models. Interestingly, in stroke patients, increased plasma levels of MMP-9, but not other MMP, have been associated with increased risk of developing hemorrhagic transformation 40, 41 . Although endothelial cells, astrocytes, neurons and immune cells can upregulate MMP-9, several studies point to the cerebrovascular endothelium as an important source of MMP-9 activity in the early stages of ischemia contributing to the early disruption of the blood brain barrier 8, 31, 42 . Altogether, our in vivo and in vitro data point to the activation of MMP-9 in the endothelium as a mechanism of induction of cerebrovascular permeability by S1PR2 after I/R injury.
Our findings are of potential translational relevance since the use and effectiveness of current stroke reperfusion therapies are limited by subsequent development of cerebrovascular complications of reperfusion injury (i.e. vasogenic edema and hemorrhagic transformation). Increased cerebrovascular permeability plays a critical role in the pathophysiology of stroke and I/R injury by allowing the entrance of neurotoxic plasma components and blood cells into the brain parenchyma, which compromises synaptic and neuronal function and by increasing intracerebral pressure, with the risk of brain herniation and/or compression of cerebral vessels, further compromising blood flow to the brain. In animal models of cerebral ischemia, blood brain barrier disruption occurs early and continues after reperfusion 25, 26 . In stroke patients, early blood brain barrier disruption is associated with hemorrhagic transformation and poor clinical outcomes 29 . Hemorrhagic transformation is a serious complication that limits the effectiveness and use of current stroke reperfusion therapies (thrombolytic and mechanical recanalization) 43 , but it may also spontaneously develop as part of the natural evolution of ischemic brain injury 44 . In this study, we found that S1PR2 inhibition potently blocked the development of spontaneous hemorrhagic transformation in experimental stroke, which was observed after a more severe ischemic injury. In addition, our findings that S1pr2 deficient mice or wild type mice, treated with the S1PR2 antagonist JTE013, exhibited a dramatic decrease in cerebral edema also raise the intriguing possibility that S1PR2 targeting could be potentially beneficial to prevent the development of malignant middle cerebral artery syndrome, in which rapid brain edema following a large MCA infarct leads to herniation and high mortality rates (80%) 45 , particularly in younger stroke patients 46, 47 . Current therapeutic options to control cerebral edema in stroke aim at decreasing intracerebral pressure by osmotherapy 48 , hyperventilation, administration of diuretics, induction of coma 49 or hypothermia, among others 50 . Although most of these conservative treatments have failed to improve mortality and disability 49, 50 , they are still being used due to the lack of alternative therapies. Only surgical decompression has been shown to be effective but only in younger patients due to the risk associated with the surgery 51 . In our study we found that S1PR2 expression is detected in brain microvessels after stroke, which together with our in vitro data with brain endothelial cells, neurons and glial cells, indicate that S1PR2 plays a critical role in the disruption of cerebrovascular integrity. We also found that the S1PR2 antagonist, JTE013, is protective when given within 4.5 hours of stroke onset (therapeutic time window). These findings have a high translational relevance and could potentially develop into novel therapies, especially with the increasing clinical use of thrombolytic or mechanical reperfusion therapies in stroke patients. In contrast to the efforts made in the development of neuroprotective drugs, very few studies have focused on the development of agents that promote cerebrovascular integrity. Our findings suggest that administration of vasoprotective agents (e.g. a S1PR2 antagonist) at the time of reperfusion could be a novel strategy to diminish cerebrovascular complications of reperfusion injury, ultimately resulting in less neurovascular injury and improved stroke outcomes [52] [53] [54] (Figure 9 ).
The pathophysiological relevance of our in vivo findings in mice is strengthened by the fact that we detected the expression of S1PR2 in the cerebrovascular endothelium in human brain samples. More specifically, we have detected S1PR2 expression in the cerebrovascular endothelium of pial vessels and microvessels in human tissue. Our human study is limited by the fact that only autopsy material was available and also by the low number of cases. A series of a larger number of cases, and ideally, biopsy specimens or autopsy material collected within few hours after death, would be required to more definitively characterize the regulation of S1PR2 expression in the cerebrovascular endothelium after ischemic/ hypoxic/inflammatory injury in the human brain. Nevertheless, we can conclude that S1PR2 is detected in the human cerebrovascular endothelium, which is consistent with a recent report by Cruz-Orengo et al. in which they found that S1PR2 is upregulated in cerebellar and spinal cord microvessels in multiple sclerosis lesions 55 . Altogether our data suggest that S1PR2 is a novel and attractive target, which deserves further study in terms of the potential for pharmacological blockade to promote cerebrovascular integrity in humans. S1PR are becoming attractive candidates for drug discovery. The most well characterized S1PR, S1PR subtype 1, was originally cloned from human endothelial cells 56 , and plays a critical role in vascular integrity 18, 19 and lymphocyte trafficking and egress from lymphoid organs 22, 57, 58 . In fact, the recently approved by FDA for the treatment of multiple sclerosis, FTY720, a potent immunosuppressor, it is an agonist of S1PR1, 3, 4 and 5. In recent studies, FTY720 has been shown to confer neuroprotection in animal models of stroke 59,60 via its immunosuppressive effects 60 but not by direct neuroprotection 59, 60 . However, FTY720 treatment is associated with increased risk of infection in multiple sclerosis patients 61 . Increasing clinical and preclinical evidence indicates that stroke-induced immunosuppression is the cause of increased vulnerability of stroke patients to infection 62, 63 , a leading cause of prolonged intensive care unit stays and increased mortality in stroke patients. Therefore, further research is still needed before considering immunomodulation (e.g. FTY720) as a therapeutic alternative for human stroke. In contrast to these previous reports 59, 60 , our study is focused on a different S1P receptor, S1PR2, which is not targeted by FTY720. Our recent work has identified endothelial S1PR2 as a robust mediator of vascular permeability and acute vascular injury in several organs in sepsis models 21 . In addition, we found no differences in immune cell trafficking between wild type and S1pr2 null mice 21 . Therefore, targeting of this novel pathway would have a potential advantage compared to targeting S1PR1 since it could lead to neurovascular protection without compromising immune function, which could be especially beneficial for stroke patients.
Recent studies from our lab indicate that S1PR2 plays a role in endothelial activation (permeability and inflammation) during acute inflammatory vascular injury 20, 21 . Upon activation with pro-inflammatory stimuli, SPHK-1 activity, the rate-limiting enzyme in S1P generation, is increased in endothelial cells 64 and S1P is released. S1PR2 expression is also induced in endothelial cells during inflammation while the levels of the other receptors do not change significantly 21 . Our in vitro data is consistent with a model in which the binding of endothelial-derived or serum-derived S1P to S1PR2 is blocked by JTE013, resulting in inhibition of brain endothelial cell activation (e.g. permeability and MMP-9 activity) after in vitro I/R injury or inflammatory challenge. The induction of MMP-9 by S1PR2 likely involves the activation of the Rho-ROCK-NF-Kappa B and the stress activated protein kinase pathways 12 , two pro-permeability and pro-inflammatory pathways that are activated by S1PR2 21 . Although S1PR2 is emerging as an important mediator of endothelial dysfunction in septic/inflammatory and ischemic vascular injury 20, 21 , it has been shown to play a protective role in anaphylactic shock via inhibition of endothelial nitric oxide synthase 65, 66 . Therefore, the effect of S1PR2 activation in terms of exacerbating or ameliorating disease appears to depend on the underlying pathophysiological setting. A better understanding of the molecular mechanisms involved in the regulation of S1PR2 expression in different vascular beds and cell lineages as well as its downstream molecular mediators is required to determine appropriate targeting strategies of the S1PR2 pathway in various pathophysiological settings.
In conclusion, our data indicate that S1PR2 plays a critical role in the disruption of neurovascular integrity after I/R injury and MMP-9 activation in brain endothelial cells. These findings reveal the novel role of S1PR2 in the pathophysiology of cerebrovascular complications of I/R injury in experimental stroke. Altogether our in vitro and in vivo data in mice and humans points to S1PR2 as an attractive therapeutic target for cerebrovascular protection in stroke and other instances of hypoxic or inflammatory injury in cerebral blood vessels.
MATERIALS AND METHODS
Mice
Mice with targeted disruption of the S1pr2 gene 23 were maintained on a mixed C57BL/ 6;129Sv genetic background (5 times backcrossed to C57BL/6). Experiments on knockout mice were performed with appropriate wild type littermate controls. All animal studies were approved by the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee.
Transient middle cerebral artery occlusion and treatments
MCAO was performed using wide type and knockout male mice (25-30g) as previously described 24, 67 . In brief, surgery was performed using a dissecting surgical microscope. Temperature was maintained at 36.5-37°C, controlled by a thermostatic blanket (TC-1000 Temperature Controller, CWE, USA) throughout the procedure. Mice were anesthetized with isoflurane, delivered by facemask in O 2 -enriched air. Blood flow in the middle cerebral artery (MCA) territory was monitored throughout the procedure using by a laser Doppler probe (PeriFlux system 5000, Ardmore, PA, USA), placed on the skull directly over the territory of the left MCA perfusion area. A midline incision was made in the neck (1.5 cm long), the common carotid (CCA) and external carotid (ECA) arteries were dissected from the adjacent tissue. After occlusion of the CCA by a microclip, the left ECA was ligated, coagulated and cut. 6-0 nylon monofilament with a round tip (approximately 0.22 mm) was introduced gently up to ~8.5-9 mm towards the origin of the MCA. The successful occlusion was verified by laser Doppler flowmetry (75-90% blood flow decrease of the baseline). After the successful occlusion, the nylon monofilament was secured in the place by ligation. 90 or 180 minutes after occlusion, the suture was withdrawn to allow reperfusion. Animals were excluded from the experimental group only if the cerebral blood flow did not decrease 75-90% during occlusion or it did not recover up to 70% of baseline within 10 min after the start of reperfusion (total 8 animals were excluded from the study). 10 minutes after reperfusion, animals were randomly assigned to the treatment groups: JTE013 (10 mg/kg or 30 mg/kg by gavage) 21 or vehicle (2% 2-hydroxypropyl β-cyclodextrin in saline). To determine the therapeutic time window of JTE013 administration, vehicle or 30mg/kg JTE013 were administered 7.5, 4.5 or 1.7 hours (10 minutes after reperfusion) after the onset of ischemia. For the 3 hour time point assays (e.g. determination of cerebrovascular permeability), JTE013 or vehicle was administered just before occlusion. After the surgery, all animals were maintained in a small animal heated recovery chamber (IMS Vetcare Chamber Recovery Unit, Harvard Apparatus, Holliston, MA).
TTC staining and determination of infarct and edema ratios
2, 3, 5-triphenyltetrazolium chloride (TTC) staining was carried out by an independent investigator to identify viable and nonviable brain tissue. Because TTC is metabolized by intact mitochondria, the red areas indicate the living tissue. Brains were harvested, sectioned into 1-mm-thick slices and incubated in a 1% solution of TTC in phosphate-buffered saline at 37°C for 5-10 min. Scanned images were used to calculate infarct and edema ratios using image analysis software (Image J, National Institutes of Health, Bethesda, MD). Infarct ratios were obtained after normalization by the contralateral (non-ischemic) hemisphere and corrected for edema as previously described 67 . Briefly, the infarct ratio (I), corrected for edema, was calculated by using the following equation: I = (X − S)/Z, where X is the area of infarct (mm 2 ), S is brain swelling (mm 2 ), S = Y − Z, Y is the area of the infarcted (ipsilateral) hemisphere slice (mm 2 ), and Z is the area of the non-infarcted (contralateral) hemisphere slices (mm 2 ). The edema ratio was calculated with the following formula: E=(Y−Z)/Z.
Neurological Score Evaluation
Neurologic examinations were carried out by an independent investigator 24 hours after tMCAO. Neurological scores were calculated as followed: 0: no deficit, 1: forelimb weakness and torso turning to the ipsilateral side when held by tail, 2: circling to affected side when held by tail on the bench, 3: spontaneous circling to the affected side or unable to bear weight on affected side and 4: no spontaneous locomotor activity or barrel rolling 67 .
In Situ Cell Death detection
DNA strand breakage during apoptosis after ischemic brain damage was assessed by a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method using the In-Situ Cell Death Detection Kit, TMR red (Roche Applied Science, Manheim, Germany), according to the manufacturer's instructions. Briefly, brain sections (30 μm) were permeabilized (0.1% Triton X-100, 0.1 % sodium citrate solution) for 5 minutes on ice and then incubated with TUNEL reaction mixture (1:10, enzyme solution: label solution) for 1 hour at 37 °C. DAPI staining was used as a counter staining. Images were captured with the Axio Imager A1 microscope, using AxioCam MRc camera and the AxioVision 4.8 program (Carl Zeiss Inc.) (original magnification, 40x). For quantification, the number of TUNEL positive cells/field from three different fields in the damaged area per mouse (bregma +1.2mm to +0.8mm, rostrally) were counted and the average values were plotted.
Evans Blue Dye (EBD) extravasation assay
To assess cerebrovascular permeability, 1 hour after reperfusion, a 2% Evans Blue dye (EBD) solution (4mL/kg) was injected into the lateral tail vein. EBD binds to plasma albumin and it can be quantified in the extravascular compartment if there is increased vascular permeability. 2 hours later, animals were anesthetized and perfused through the left ventricle with ice-cold PBS to remove intravascular EBD. Brains were harvested, sliced and scanned. Then, the hemispheres were separated and mechanically homogenized in 50% trichloroacetic solution. After centrifugation (20,000 g for 20 minutes), supernatants were diluted 1:3 with ethanol. The amount of extravascular EBD was calculated by measuring the fluorescence (620 excitation, 680 emission). Ipsilateral/Contraleral ratios were calculated and plotted.
Quantification of extravascular hemoglobin
To assess hemorrhagic transformation, 24 hours after a 3 hour-occlusion period, mice were anesthetized and perfused through the left ventricle with a 5mM EDTA-saline solution. Brains were harvested, sliced and scanned. Then, the ipsilateral and contralateral hemispheres were separated and homogenized in PBS. After sonication, the homogenates were centrifuged at 13,000 rpm for 30 minutes at 4°C and extravascular hemoglobin was quantified using the QuantiChrom TM Hemoglobin Assay Kit (BioAssay Systems, Hayward, CA) following manufacture's instructions. The amount of hemoglobin in brain homogenates was calculated using a standard curve. Ipsilateral/Contraleral ratios were calculated and plotted.
Determination of gelatinase activity in brain lysates
Three hours after reperfusion mice were perfused through the left ventricle with ice-cold PBS and brains were removed and frozen in liquid nitrogen. Brain tissue was homogenized in lysis buffer (50mmol/L Tris-HCL pH 7.6, 150 mmol/L NaCl, 5 mmol/L CaCl2, 0.05% Brij-35, 0.02% NaN3, and 1% Triton X-100) and centrifuged at 13,000 rpm for 20 minutes 10 . 0.8 mg protein in 500 μl lysis buffer was incubated with 40 μl (bead volume) of gelatin-Sepharose 4B beads (GE Healthcare, Piscataway, NJ, USA) for 1 hour at 4°C with gentle rotation to pull down MMP from brain homogenates. The beads were washed three times with lysis buffer and were resuspended in 30 μL of elution buffer (10% dimethylsulfoxide in lysis buffer) for 30 minutes. The supernatants were collected and then each sample was mixed with equal amounts of SDS sample buffer (Invitrogen Life Technologies, Carlsbad, CA, USA). The samples were loaded on 10% SDS-polyacrylamide electrophoresis gels with 0.1% porcine skin gelatin as a substrate (Invitrogen Life Technologies). After electrophoresis, the gels were incubated with renaturing buffer (2.5% Triton X-100 in H 2 O) for 30 minutes to remove the SDS and then incubated for 24 hours (for MMP-2) or 48 hours (for MMP-9) at 37°C with developing buffer (Invitrogen Life Technologies). After incubation, gels were stained for 60 minutes in Coomassie blue R-250 (0.25%Coomassie brilliant blue R-250, 50% methanol, 10% acetic acid) and de-stained in 40% methanol and 10% acetic acid until clear bands of gelatinolysis appeared on a blue background. Human MMP-2 and MMP-9 were used as a gelatin standard (Chemicon International Inc. Temecula, CA, USA). The images were scanned and quantification was performed using Image J program.
In situ zymography in ischemic brain tissue
Mice were euthanized three hours after reperfusion and perfused through the left ventricle with ice-cold PBS. Brains were removed, quickly frozen and kept at −80°C. To assess gelatinase activity in situ, fresh sham and ischemic brain slices (14 μm) were incubated with a reaction solution including DQ gelatin conjugated with fluorescein (Life technologies, Carlsbad, CA) for 6 hours at 37°C. Sections were then washed 3 times with PBS and subsequently incubated with DAPI for nuclear staining. Images were captured with the Axio Imager A1 microscope, using AxioCam MRc camera and the AxioVision 4.8 program (Carl Zeiss Inc.) (original magnification, 40x).
Immunostaining for S1PR2 detection
Mice were anesthetized with Avertin and were perfused with cold PBS and subsequently with 4% PFA in PBS solution. The brains were removed, post-fixed with 4% PFA for 24 h and transferred to 30% sucrose solution. Frozen brains were cut with a thickness of 30 μm in a cryostat. Slices were preserved in 30%PEG 30% sucrose PBS. The brain slices were washed three times with Tris-buffered saline (TBS) and were then blocked with TBSblocking solution (1 % bovine serum albumin, 0.2 % skim milk, and 0.3 % Triton X-100 in TBS) for 1 h and incubated with the following primary antibodies in TBS-blocking solution overnight on a shaker at 4 °C. Rabbit anti-S1P2R antibody (1:100, Proteintech Group Inc., Chicago, IL), rat anti-CD31 antibody (1:100, BD Biosciences, Pharmingen, San Jose, CA) were used as primary antibodies. Sections were washed three times with Tris-buffered saline (TBS) and then they were incubated with donkey anti-rabbit IgG-Alexa-594, goat anti-rat IgG Alexa-488 (1:250, Life Technologies, Molecular Probes, Grand Island, NY). Brain slices were stained with 4′,6-diamidino-2-phenylindole (DAPI) for 7 minutes and were mounted onto slides. Samples were observed on an Zeiss LSM 510 Meta Confocal microscope (Carl Zeiss Inc.). Images were captured using Zen LE software (Carl Zeiss). The specificity of the S1PR2 antibody was confirmed by lack of signal in the S1pr2 −/− brain sections.
Brain endothelial cell culture and in vitro I/R studies
The mouse brain endothelial cell line bEnd.3 (ATCC (passages 25-35) (ATCC) 33 was cultured in DMEM supplemented with 10% FBS. Passages 25-35 were used. Human primary brain microvessel endothelial cells (hMVBEC) (Cell Systems Corporation, Kirkland, WA) were cultured as recommended by the manufacturer. Passages 5-9 were used.
To mimic in vitro the metabolic and inflammatory stress of I/R injury, oxygen and glucose deprivation (OGD) and TNF-α activation studies were conducted.
Brain endothelial cells were exposed to hypoxia (1% O 2 )/aglycemia for 6 hours in a hypoxia polymer glove box (Coy Lab Products Inc., MI). Then, the media was aspirated and replaced with complete growth media (which contains glucose) and cells were placed in a normoxic atmosphere. For the permeability studies, the media contained serum and changes in endothelial resistance after reperfusion were measured using the electrical cell-substrate impedance sensing system (ECIS) (Applied BioPhysics, NY) 34 . For the TNF-α activation studies, cells were stimulated with 5 ng/mL TNF-α in serum-free media containing growth factors (Cell Systems Corporation).
Assessment of brain endothelial cell permeability
bEnd3.3 cells were grown to confluence in disposable electrode arrays containing gold film electrodes (Applied BioPhysics, NY), previously coated with human fibronectin and collagen IV (50 μg/mL) and exposed to hypoxia (1% O 2 )/aglycemia for 6 hours in a hypoxia polymer glove box (Coy Lab Products Inc., MI). Then, the media was aspirated and replaced with complete growth media (which contains glucose and 10% fetal bovine serum), cells were placed in a normoxic atmosphere and changes in endothelial resistance upon reperfusion were measured using the electrical cell-substrate impedance sensing system (ECIS) (Applied BioPhysics) 34 
MMP activity in brain endothelial cell supernatants
For in vitro detection of MMP-2 and MMP-9 activity, conditioned media from hBMVEC, subjected to TNF-α treatment were used. hBMVEC were grown on 12 well plates. Cells were treated with TNF-α (5ng/ml) in serum-free complete growth media (Cell Systems Corporation) for 24 hours. Conditioned media were collected, spun down, 10μl of supernatants were mixed with equal amounts of SDS sample buffer and gelatin zymography was conducted as described above.
Primary cortical neuron isolation and in vitro I/R studies
Mouse (C57BL6) E16.5 embryos were used for primary cortical neuron isolation as previously described 68 . Briefly, the cortices were collected and incubated with 0.25% trypsin for 15 min at 37°C for tissue digestion. Fetal bovine serum was added to stop the trypsin activity. After centrifugation, the supernatant was discarded and DMEM complete media containing 10% FBS and antibiotics were added to the cells. The cell suspension was passed though 70 μm cell strainer (BD Biosciences, Falcon) and was plated on poly-L-lysine (Sigma Aldrich, St Louis MO)-coated dishes with DMEM complete media. The next day, the medium was changed to Neurobasal media containing B27 supplement, antibiotics, and GlutaMAX (Life Technologies, Grand Island, NY). At 7 days in vitro (DIV), the cells (> 95% NeuN positive) were used for the in vitro I/R injury assays. Neurons were subjected to hypoxia (1% O 2 )/aglycemia for 4 hours in a hypoxia polymer glove box (Coy Lab Products Inc.). Then, the media was aspirated and replaced with complete growth media (which contains glucose) in the presence or absence of vehicle, α-PBN or JTE013 and cells were placed in a normoxic atmosphere. Cells were harvested for RNA isolation, reverse transcription and quantitative PCR analysis (RT-qPCR), 6 or 24 hours after in vitro reperfusion to determine S1PR2 mRNA levels. LDH activity was assessed 24 hours after reperfusion. To mimic the oxidative stress characteristic of I/R injury, neurons were treated with 30μM H 2 O 2 in the presence or absence of vehicle, α-PBN or JTE013 for 24 hours and LDH activity was assessed in neuronal supernatants.
Lactate dehydrogenase activity (LDH) Assay
Neuronal cytotoxicity was assessed by measuring LDH activity in the media, 24 hours after in vitro I/R injury or H 2 O 2 treatment, using the Cytotoxicity Detection Kit (Roche Applied Science), as instructed by the manufacturer. Data were plotted as fold change compared with non-treated control cells. α-PBN was used as a positive control for oxidative stress-induced cell death blocker 35 .
Mixed glial cell culture and activation
Mixed glial cell culture was prepared using the mouse brains from postnatal day 2 mouse. Briefly, cerebral cortices were dissected, trypsinized with of 0.25% trypsin-EDTA in HBSS and were incubated with trypsin (Thermo scientific) and DNase (Worthington) for 15 minutes at 37 C. Fetal Bovine Serum was added to the cell suspension to stop trypsin digestion. Cell suspension was centrifuged and the pellet was resuspended with DMEM containing 20% FBS, and antibiotics. Cell suspension were filtered with a 100 um cell strainer (BD Falcon) into another 50 ml conical tube. Cells were plated onto 6 well plates, which were pre-coated with poly-D-lysine. Three days after plating, the media was changed to DMEM containing 10% FBS and antibiotics. Cells were maintained in DMEM containing 10% FBS and antibiotics at 37 C with 5% CO2, with a medium change every 3 days. At day 10 after plating, mixed glial cells were treated with 5ng/mLTNF-α to mimic the proinflammatory environment of I/R injury. 24 hours later, MMP activity was assessed in the supernatants as described below and glial cells were harvested for RNA isolation and RT-qPCR analysis to determine S1PR2 mRNA levels.
S1PR2 Immunohistochemistry
Immunohistochemistry for S1PR2 was performed on an automated stainer (Leica Bond III, Leica Biosystems, Buffalo Grove, IL) using an anti-human S1PR2 rabbit polyclonal antibody (catalog # HPA014307, Sigma Aldrich) at a final dilution of 2 ug/ml. 5μm formalin fixed paraffin embedded tissue sections and cell pellets were deparaffinized and processed using heat induced epitope retrieval with an EDTA-based buffer (Leica #AR9640) for 20 minutes and incubated with primary antibody for 30 minutes at room temperature. Postprimary reagent (polymer anti-rabbit poly-HRP-IgG, less than 25 ug/mL, Leica # DS9800) was incubated for 10 minutes at room temperature and staining was visualized with diaminobenzidine for 10 minutes (Leica # DS9800). Pictures were taken with a 60x objective using Olympus BX41 Camera and CellSens Entry Imaging Software. Cases were retrieved from Brigham and Women's Department of Pathology archives and this work was approved by the Institutional Review Board (Protocol #2013P001431).
RNA isolation
To prepare mouse organ tissue lysates, mice were perfused with PBS containing 2 mM EDTA, organs were removed and snap frozen in liquid nitrogen. Organs were homogenized and total RNA was prepared using RNeasy Mini Kit (Qiagen, Valencia, CA) with RNasefree DNase treatment (Qiagen) to remove the genomic DNA.
Reverse transcription and quantitative TaqMan PCR analysis
To generate cDNA, 100 ng of RNA was reverse transcribed using random primers and SuperScript II RT-polymerase (Invitrogen, Carlsbad, CA). Primers were designed using the Primer Express oligo design program software (Applied Biosystems, Foster City, CA). All primer sets were subjected to rigorous database searches to identify potential conflicting transcript matches to pseudogenes or homologous domains within related genes. PCR primer sequences for target molecules were previously described 21 and shown in Supplementary Table 2. Amplicons generated from the primer set were analyzed for melting point temperatures using the first derivative primer melting curve software supplied by Applied BioSystems. Real-time quantitative PCR was performed using the SYBR Green I assay on the ABI 7500 Sequence Detection System (Applied Biosystems). PCR reactions for each cDNA sample were performed in duplicate and copy numbers were calculated using standard curves generated from a master template as previously described 69 . Briefly, each cDNA template was purified, precisely quantified, and tenfold serially diluted to produce a series in which the lowest-concentration dilution has a single copy per microliter. To generate a standard curve, the threshold cycle (Ct) values for each dilution in the template series are plotted as a function of the logarithm of the known input template numbers and a linear trendline is fitted to the data.
Statistical analyses, randomization and blinding
All values reported are mean±SEM. P values were calculated with GraphPad Prism software, using i) one-way ANOVA followed by Newman-Keuls test or ii) Student's t test when comparing two groups. The criterion for statistical significance was set at P<0.05.
All animal experiments used randomization to treatment groups and blinded assessment 70 .
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Fig. 1. Inhibition of S1PR2 results in less edema and neuronal injury in experimental stroke
Ischemia (90 min.) was induced in wild type (S1pr2 +/+ ) and S1pr2 −/− by MCAO. After reperfusion mice received vehicle or the S1PR2 antagonist, JTE013 (30mg/kg), by gavage. A) Representative images of TTC staining of 7, 1 mm-thick brain coronal slices 24 hours after reperfusion. Scale bar 5 mm. B) Edema and C) Infarct ratios were calculated by image analysis and reported as a ratio of the non-ischemic hemisphere. Infarct ratios were corrected for edema. The individual values and the mean ± SEM are shown. N=10-13 from 8 independent experiments. *p<0.05 (one-way ANOVA followed by Newman-Keuls). D) Improved neurological scores (i.e., lower neurological deficit scores) were observed in S1pr2 −/− or JTE013-treated S1pr2 +/+ mice compared to vehicle-treated S1pr2 +/+ , 24 hours after reperfusion. E) Representative pictures of TUNEL assay (red channel) in the damaged area from S1pr2 +/+ , S1pr2 −/− and JTE013-treated S1pr2 +/+ mice. Blue channel: nuclear staining (DAPI). F) Quantification of TUNEL positive cells per mm 2 . Values are the average of TUNEL positive cells from three fields. n=4-8 from 4 independent experiments. Scale bar: 50μm. G) Image showing the anatomical areas in which TUNEL positive cells were quantified in mice (bregma +1.2mm to +0.8mm, rostrally). Scale bar 2.5 mm. Regional CBF in the middle cerebral artery territory was measured throughout the surgeries using a laser Doppler probe, attached to the temporal bone. The relative CBF (% of basal) during MCA occlusion (I, red circles, squares and triangles) and 10 minutes after reperfusion (R, green circles, squares and triangles) is shown in S1pr2 +/+ , S1pr2 −/− and S1pr2 +/+ receiving JTE013 is shown. N=18-30.
Fig. 4. Blockade of S1PR2 results in decreased MMP-9 activity in ischemic brains
A) Representative zymographies showing MMP-9 and MMP-2 activity, 3 hours after I/R in whole brain homogenates, in sham (S), vehicle-treated S1pr2 +/+ (S1pr2 +/+ ), vehicle-treated S1pr2 −/− (S1pr2 −/− ) and JTE013-treated S1pr2 +/+ mice (S1pr2 +/+ +JTE013). Arrows indicate active MMP-9 and MMP-2. B) Quantification of gelatinase activity by image analysis. Values are normalized by the average gelatinase activity in wild type mice after I/R injury. N=4-15 from 5 independent experiments. # p<0.05 sham vs MCAO, *P≤0.05 vehicletreated S1pr2 +/+ vs JTE013-treated S1pr2 +/+ or vehicle-treated S1pr2 −/− (one-way ANOVA followed by Newman-Keuls). C) Representative pictures of the damaged area (at the level of bregma +1.2mm to +0.8mm, rostrally, as indicated in Figure 1G ) (n=5-6 per group, from 4 independent experiments) of the in situ gelatinase assay in frozen brain sections (14 μm) using FITC DQ-gelatin are shown. Notice significantly lower gelatinase activity in brain microvessels in vehicle-treated S1pr2 −/− or JTE013-treated S1pr2 +/+ mice compared to vehicle-treated wild type, 3 hours after reperfusion. Scale bar 50 μm.
Fig. 5. Upregulation of S1PR2 in brain microvessels after I/R injury
A) S1PR2 mRNA levels in the ipsilateral hemisphere of brain homogenates from sham animals and MCAO animals, 6 hours (6h I/R) or 24 hours (24h I/R) after tMCAO. The fold induction of S1PR2 mRNA levels (normalized by 18s RNA) vs sham is shown. *p<0.05 (one-way ANOVA followed by Newman-Keuls). B-D) S1PR2 (red channel) and CD31 (green channel) immunofluorescence analysis in brain sections from the ipsilateral (B) or contralateral (C) hemisphere of wild type mice or ipsilateral hemisphere of S1pr2 −/− mice (D), 6 hours after tMCAO. Representative pictures of the corpus callosum at the level of bregma +1.2mm to +0.8mm, rostrally, as indicated in Figure 1G , are shown (n=5-6 per group). S1PR2 was detected only in cerebral microvessels in the damaged area (ipsilateral hemisphere, B) but not in the contralateral hemisphere (C), the ipsilateral hemisphere of S1pr2 −/− mice (D) or in sham animals (not shown). Arrows indicate the S1PR2 and CD31 positive areas. Scale bar 50 μm. A, B) Induction of S1PR2 mRNA in bEnd.3 and hBMVEC after in vitro I/R injury or activation with TNF-α. Brain endothelial cells were subjected to A) 6 hours of OGD followed by in vitro reperfusion or B) activation with TNF-α (5ng/mL). 6 hours later, RNA was isolated and S1PR2 mRNA levels were quantified by qRT-PCR analysis. Fold induction of S1PR2 mRNA (normalized by 18s RNA) vs control (C) is shown. * P≤0.05 in vitro I/R or TNF-α vs control (Student's t test). Values are mean±SEM, n=4. C, D) S1PR2 inhibition by JTE013 prevented the decrease in monolayer resistance in bEnd. Mouse primary neurons (A-C) and mouse primary mixed glial cells (D, E) were isolated and cultured as described in the method section. A) Mouse primary neurons were subjected to 4 hours of OGD. 6 or 24 hours after in vitro reperfusion RNA was isolated and S1PR2 mRNA copy number was calculated by RT-qPCR analysis and normalized by 10 6 copies of 18s RNA. Fold induction vs control (C, normoxia, normoglycemia) is plotted. B) Mouse primary neurons were subjected to 4 hours of OGD. Upon in vitro reperfusion, cells were treated with vehicle (V), α-PBN (1mM) or JTE013 (1μM) for 24 hours. Neuronal cell death was assessed by measuring LDH activity in the supernatants. C) Primary neurons were treated with H 2 O 2 (30μM) for 24 hours in the presence or absence of 1mM α-PBN or 1μM JTE 013 (JTE) and LDH activity was measured. Control: no H 2 O 2 . V: vehicle. D, E) Mouse primary mixed glial cells were activated with 5ng/mL TNF-α to mimic the proinflammatory environment of I/R injury. 24 hours later, S1PR2 (D) and IL-1β (E) mRNA levels were assessed by RT-qPCR analysis. F) Mouse primary mixed glial cells were activated with 5ng/mL TNF-α in the presence or absence (vehicle) of JTE013 at the doses indicated (μM). MMP-9 and MMP-2 activity in the conditioned media was assessed by gelatin zymography. Values are mean ± SEM. n=3 from 3 independent experiments. A representative zymography is shown. * P≤0.05 TNF-α vs control, and when indicated, TNF-α vs TNF-α +JTE013-treated (one-way ANOVA followed by Newman-Keuls). St: active MMP-9 standard. A-E) Fold induction vs control is plotted.
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